关于短期口服福斯拉康唑治疗足癣的探索性研究

Yuichiro Tsunemi, Wataru Naka
{"title":"关于短期口服福斯拉康唑治疗足癣的探索性研究","authors":"Yuichiro Tsunemi, Wataru Naka","doi":"10.1111/1346-8138.17455","DOIUrl":null,"url":null,"abstract":"We investigated the clinical efficacy of short‐term, oral fosravuconazole (F‐RVCZ) therapy for tinea pedis, commonly known as athlete's foot. F‐RVCZ (equivalent to 100 mg ravuconazole) was administered orally once daily for 1 week for interdigital and vesicular tinea pedis and for 4 weeks for hyperkeratotic tinea pedis. Efficacy was evaluated based on mycological efficacy and clinical symptoms at Weeks 1, 4, and 8 for interdigital and vesicular tinea pedis and at Weeks 4, 8, and 12 for hyperkeratotic tinea pedis. Efficacy was confirmed at the end of treatment. Therapeutic efficacy increased over time from the end of treatment for both types of tinea pedis. All adverse drug reactions (ADRs) were within expectations and there were no cases of discontinuation due to ADRs or serious ADRs. Short‐term oral F‐RVCZ therapy is expected to be as effective or more effective than terbinafine and itraconazole, which have already been approved in Japan and may be a useful option for the treatment of tinea pedis.","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploratory study on short‐term administration of oral fosravuconazole for tinea pedis\",\"authors\":\"Yuichiro Tsunemi, Wataru Naka\",\"doi\":\"10.1111/1346-8138.17455\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We investigated the clinical efficacy of short‐term, oral fosravuconazole (F‐RVCZ) therapy for tinea pedis, commonly known as athlete's foot. F‐RVCZ (equivalent to 100 mg ravuconazole) was administered orally once daily for 1 week for interdigital and vesicular tinea pedis and for 4 weeks for hyperkeratotic tinea pedis. Efficacy was evaluated based on mycological efficacy and clinical symptoms at Weeks 1, 4, and 8 for interdigital and vesicular tinea pedis and at Weeks 4, 8, and 12 for hyperkeratotic tinea pedis. Efficacy was confirmed at the end of treatment. Therapeutic efficacy increased over time from the end of treatment for both types of tinea pedis. All adverse drug reactions (ADRs) were within expectations and there were no cases of discontinuation due to ADRs or serious ADRs. Short‐term oral F‐RVCZ therapy is expected to be as effective or more effective than terbinafine and itraconazole, which have already been approved in Japan and may be a useful option for the treatment of tinea pedis.\",\"PeriodicalId\":94236,\"journal\":{\"name\":\"The Journal of dermatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of dermatology\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.1111/1346-8138.17455\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatology","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1111/1346-8138.17455","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

我们研究了短期口服福斯拉康唑(F-RVCZ)治疗脚癣(俗称香港脚)的临床疗效。F-RVCZ(相当于 100 毫克雷武康唑)每天口服一次,治疗趾间癣和水泡型足癣 1 周,治疗角化过度型足癣 4 周。根据霉菌学疗效和临床症状,在第 1、4 和 8 周对足间癣和水泡型足癣进行疗效评估,在第 4、8 和 12 周对角化过度型足癣进行疗效评估。疗效在治疗结束时得到确认。两种类型的足癣疗效均在治疗结束后随时间推移而增加。所有药物不良反应(ADR)均在预期范围内,没有因药物不良反应或严重药物不良反应而停药的病例。预计短期口服 F-RVCZ 的疗效与特比萘芬和伊曲康唑相同或更佳,这两种药物已在日本获得批准,可能是治疗足癣的有效选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploratory study on short‐term administration of oral fosravuconazole for tinea pedis
We investigated the clinical efficacy of short‐term, oral fosravuconazole (F‐RVCZ) therapy for tinea pedis, commonly known as athlete's foot. F‐RVCZ (equivalent to 100 mg ravuconazole) was administered orally once daily for 1 week for interdigital and vesicular tinea pedis and for 4 weeks for hyperkeratotic tinea pedis. Efficacy was evaluated based on mycological efficacy and clinical symptoms at Weeks 1, 4, and 8 for interdigital and vesicular tinea pedis and at Weeks 4, 8, and 12 for hyperkeratotic tinea pedis. Efficacy was confirmed at the end of treatment. Therapeutic efficacy increased over time from the end of treatment for both types of tinea pedis. All adverse drug reactions (ADRs) were within expectations and there were no cases of discontinuation due to ADRs or serious ADRs. Short‐term oral F‐RVCZ therapy is expected to be as effective or more effective than terbinafine and itraconazole, which have already been approved in Japan and may be a useful option for the treatment of tinea pedis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信